Development asset linked to GeneScience Pharmaceuticals Co in public FDA and regional records.
pharma · Advanced Gastric or Gastroesophageal Junction Cancer · Dwarfism
GeneScience Pharmaceuticals Co
Changchun GeneScience Pharmaceutical Co.,
GeneScience Pharmaceuticals Co drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
30 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 30
- Programs
- 3
- Drugs
- 4
- Patents
- 0
GeneScience Pharmaceuticals Co pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
GeneScience Pharmaceuticals Co drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to GeneScience Pharmaceuticals Co in public FDA and regional records.
-
somatropin
Systemic hormonal preparations (H01)US regulatory status: approved. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
Development asset linked to GeneScience Pharmaceuticals Co in public FDA and regional records.